Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Acrux Limited

Market Cap 8.73M 6.17M 5.31M 4.89M 4.59M 8.63M 583M 57.72M 22.51M 287M 23.13M 22.64M 989M P/E Ratio 2024
-3.44x
P/E Ratio 2025 -0.95x
Enterprise Value 11.5M 8.13M 7M 6.44M 6.05M 11.37M 769M 76.06M 29.66M 378M 30.48M 29.84M 1.3B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day+6.25%
1 week+41.67%
Current month+41.67%
1 month+54.55%
3 months+41.67%
6 months+6.25%
Current year+13.33%
1 week 0.01
Extreme 0.012
0.02
1 month 0.01
Extreme 0.009
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.16
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 31/05/2025
Director of Finance/CFO - 20/06/2021
Chief Tech/Sci/R&D Officer - 14/02/2015
Director TitleAgeSince
Chairman 74 31/12/2005
Director/Board Member - 30/09/2013
Director/Board Member 70 31/05/2016
Change 5-day change 1-year change 3-year change Capi.($)
+6.25%+41.67%-22.73%-63.83% 5.82M
-0.29%+0.67%+6.69%+82.18% 45.85B
+1.27%-1.80%+42.88%+87.04% 33.63B
-0.59%-1.06%-8.77%+37.57% 11.81B
-0.86%-0.82%+10.64%+96.43% 11.59B
+1.54%+3.12%+40.43%+132.60% 9.28B
-1.73%-1.89%+18.15%+42.12% 7.33B
-0.26%+0.49%+44.71%-15.55% 6.65B
+0.00%-0.91%+29.15%+235.70% 6.44B
-3.10%-2.79%-44.79%-6.76% 5.16B
Average +0.22%+3.07%+11.64%+62.75% 13.77B
Weighted average by Cap. -0.03%-0.37%+18.37%+81.13%

Financials

2024 2025
Net sales 5.09M 3.6M 3.1M 2.85M 2.68M 5.03M 340M 33.68M 13.13M 167M 13.5M 13.21M 577M 1.19M 841K 724K 667K 626K 1.18M 79.54M 7.87M 3.07M 39.08M 3.16M 3.09M 135M
Net income -5.8M -4.1M -3.53M -3.25M -3.05M -5.73M -388M -38.37M -14.96M -190M -15.38M -15.05M -657M -5.94M -4.2M -3.62M -3.33M -3.13M -5.88M -397M -39.33M -15.33M -195M -15.76M -15.43M -674M
Net Debt 759K 536K 462K 425K 399K 750K 50.73M 5.02M 1.96M 24.93M 2.01M 1.97M 86.04M 2.77M 1.96M 1.69M 1.55M 1.46M 2.74M 185M 18.34M 7.15M 91.04M 7.35M 7.19M 314M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
16/06/26 0.0170 $ +6.25% 1,027,700
15/06/26 0.0160 $ -5.88% 124,024
12/06/26 0.0170 $ -5.56% 2,127,316
11/06/26 0.0180 $ +12.50% 3,458,763
10/06/26 0.0160 $ +33.33% 5,602,843

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!